Unloading the heart in congestive heart failure.

[1]  J. Cohn,et al.  Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure. , 1984, Journal of the American College of Cardiology.

[2]  J. Cohn,et al.  Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. , 1984, Circulation.

[3]  J. Cohn,et al.  Hemodynamic and hormonal response to transdermal nitroglycerin in normal subjects and in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[4]  J. Cohn,et al.  The effects of bromocriptine in patients with congestive heart failure. , 1983, American heart journal.

[5]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[6]  E. Sonnenblick,et al.  Sustained Hemodynamic and Clinical Effects of a New Cardiotonic Agent, WIN 47203, in Patients with Severe Congestive Heart Failure , 1983, Circulation.

[7]  P. Reddy,et al.  The Acute Hemodynamic Effects of a New Agent, MDL 17,043, in the Treatment of Congestive Heart Failure , 1983, Circulation.

[8]  J. Cohn,et al.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. , 1982, The American journal of cardiology.

[9]  J. Cohn,et al.  Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure. , 1982, The American journal of cardiology.

[10]  T. Giles,et al.  Short‐term effects of intravenous clonidine in congestive heart failure , 1981, Clinical pharmacology and therapeutics.

[11]  R. Gorlin,et al.  Determinants of Drug Response in Severe Chronic Heart Failure. 1. Activation of Vasoconstrictor Forces During Vasodilator Therapy , 1981, Circulation.

[12]  J. Cohn,et al.  Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. , 1980, The American journal of medicine.

[13]  J. Cohn,et al.  Acute and Long‐term Response to an Oral Converting‐enzyme Inhibitor, Captopril, in Congestive Heart Failure , 1980, Circulation.

[14]  K. Swedberg,et al.  PROLONGATION OF SURVIVAL IN CONGESTIVE CARDIOMYOPATHY BY BETA-RECEPTOR BLOCKADE , 1979, The Lancet.

[15]  J. Franciosa,et al.  Immediate Effects of Hydralazine-Isosorbide Dinitrate Combination on Exercise Capacity and Exercise Hemodynamics in Patients with Left Ventricular Failure , 1979, Circulation.

[16]  J. Cohn,et al.  Effect of isosorbide dinitrate on response to submaximal and maximal exercise in patients with congestive heart failure. , 1979, The American journal of cardiology.

[17]  R. Gorlin,et al.  Hemodynamic and Clinical Tachyphylaxisc to Prazosin-Mediated Afterload Reductionin Severe Chronic Congestive Heart Failure , 1979, Circulation.

[18]  J. Cohn,et al.  Role of the Renin-Angiotensin System in the Systemic Vasoconstriction of Chronic Congestive Heart Failure , 1978, Circulation.

[19]  J. Cohn,et al.  Hemodynamic effects of trimazosin in patients with left ventricular failure , 1978, Clinical pharmacology and therapeutics.

[20]  J. Cohn,et al.  Vasodilator Therapy of Cardiac Failure , 1977 .

[21]  J. Cohn.  Blood pressure and cardiac performance. , 1973, The American journal of medicine.

[22]  J. Ross,et al.  Oxygen consumption of the heart. Newer concepts of its multifactoral determination. , 1968, The American journal of cardiology.

[23]  J. Wood.  The mechanism of the increased venous pressure with exercise in congestive heart failure. , 1962, The Journal of clinical investigation.

[24]  A. Barger.  The pathogenesis of sodium retention in congestive heart failure. , 1956, Metabolism: clinical and experimental.